A world where people with cancer live better and longer lives, that’s Pfizer Oncology’s vision. We are accelerating breakthrough medicines that bring new hope to patients everywhere. Many of these breakthroughs are biologic buy-and-bill products like Elrexfio and Padcev, among others in our pipeline. By 2030, we anticipate biologics will account for 65% of the Pfizer Oncology business vs. today’s 6%. At a time of rapid market evolution, account consolidation, increasing account influence and a shift in the definition of value in the US oncology marketplace, business success in buy-and-bill biologics requires a deep understanding of provider dynamics and a careful balance of near-term actions with long-term impact. To address this, US Oncology has built a market-leading buy-and-bill capability to spearhead provider strategy for our growing portfolio of biologic medicines. The Director, Biologics Value Strategy is a key member of the Oncology organization. This colleague will be aligned to one or more of brands/franchises, which include Pfizer Oncology future growth engines like Elrexfio, Acetris, Padcev, and SV. He/she will be responsible for financial modeling, ASP forecasting and analytics of buy-and-bill contracting models across hospital systems, GPO customer segments and key accounts. The Director, Biologics Value Strategy will report directly to the Biologics Value Strategy Team Lead and will also work closely with their peer Value Strategy Lead, US Franchise and Brand Leads, National Accounts, cKAD and USMA teams, among others, to support the Franchise objectives through strategic contracting expertise.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director